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Summary Background. Polysensitization, defined as being allergic to three or more haptens from the European
baseline series, is considered to reflect increased susceptibility to developing a contact allergy, and is likely
to be associated with an impaired quality of life.
Objectives. To evaluate the prevalences of polysensitization across Europe and to analyse factors associ-
ated with polysensitization.
Methods. Patch test data collected by the European Surveillance System on Contact Allergies (ESSCA;
www.essca-dc.org) in consecutively patch tested patients from January 2009 to December 2014, com-
prising 11 countries and 57 departments, were retrospectively analysed.
Results. A total of 86 416 patients were available for analysis, showing a standardized prevalence of
polysensitization of 7.02%, ranging from12.7% (Austria) to 4.6% (Italy). Allergen pairswith the strongest
association are reported for the total population, for South Europe, and for North/Central Europe. Overall,
polysensitized patients showed a higher percentage of extreme (+++) positive patch test reactions than
oligosensitized patients. Female sex, occupational dermatitis and age >40 years were risk factors for
polysensitization.
Conclusions. The varying prevalences of polysensitization across Europemost likely reflect differences in
patient characteristics and referral patterns betweendepartments. Known risk factors for polysensitization
are confirmed in a European dermatitis population.
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Polysensitization, in terms of multiple contact allergies,
is currently defined as sensitization to three or more
non-related allergens of the European baseline series
(EBS) (1). Although arbitrarily defined, this concept
is used both to investigate risk factors for developing
multiple contact allergies, and to address the topic of
increased susceptibility, for example caused by genetic
variants (2). For example, polysensitization was shown to
be associated with certain genetic markers with links to
pathogenetic steps of allergic contact dermatitis (ACD) (3,
4), reflecting increased susceptibility independently from
actual haptens (5), which implies that allergen-specific
susceptibilities should be considered as well (5, 6). Poly-
sensitization has been extensively reviewed by Carlsen
et al. and Schnuch et al. (7, 8). The main cause of acquir-
ing multiple sensitivities is apparently high exposure to
environmental allergens, for example by occupational
exposure, or pre-existing inflammatory dermatoses con-
veying ‘danger signals’ [e.g. in patients with leg (stasis)
dermatitis or leg ulcers] (9). Studies have shown, how-
ever, that polysensitized individuals, when sensitized in
an experimental setting, have a lower elicitation thresh-
old and generally show stronger elicitation reactions
than single/double-sensitized individuals, providing
arguments for different susceptibilities between these
groups (10, 11).
Although quality of life has not been thoroughly inves-
tigated in polysensitized patients, one case–control study
investigatingquality of life in fragrance-allergic dermatitis
patients as comparedwith dermatitis patientswith no fra-
grance allergy found an increase in impairment in quality
of life with an increasing number of positive patch test
reactions to fragrance allergens (12, 13). Polysensitized
individuals have ahigher probability of relevant exposure,
and therefore it is not difficult to imagine that they suffer
more from persistent dermatitis and frequent relapses of
their dermatitis.
The reported prevalences of polysensitization in patch
test populations depends greatly on the tested population
and the length of the tested baseline series, yielding preva-
lences ranging from5.0% to almost 20.0% (this last result
was based on a baseline series consisting of 73–80 aller-
gens) (1, 11, 14). The prevalence of polysensitization in
the largest reported group, that of the Information Net-
work of Departments of Dermatology (IVDK) in Germany,
has been found to be stable around 10.0% (15, 16). In
one study, the prevalence of polysensitization found in a
small general population sample was 0.7% (17).
The objective of this study was to evaluate prevalences
of polysensitization in different European countries. We
also aimed to evaluate factors associated with polysensi-
tization in patients who were patch tested at departments
of the European Surveillance System on Contact Allergies
(ESSCA) network in the period from 2009 to 2014.
Methods
The analysis is based on clinical data collected by the
ESSCA network, as described in previous publications
(18, 19). Briefly, clinical and demographic data, along
with patch test results, of all patients patch tested in
the departments participating in the ESSCA for suspected
ACD caused by various potential exposures are docu-
mented electronically in the local departments. These use
diverse data capture software and, partly, themultilingual
software WINALLDAT/ESSCA provided by the ESSCA (20).
Standardized patch testing follows international recom-
mendations (21). The anonymized data delivered by the
participants are pooled in the ESSCA data centre in Erlan-
gen for further analysis, (22) with R (version 3.2.3) soft-
ware (www.r-project.org, last accessed 22 March 2017).
Pertinent guidelines for the statistical analysis of patch
test data were considered (23, 24).
For analysis, the maximum patch test reactions
between day (D) 3 and D5 (inclusive) were aggregated
as the patch test outcome. Reactions designated as
either +, ++ or +++ were classified as positive (allergic),
and the remainder were classified as non-allergic. The
study period was January 2009 to December 2014, and
included, for the present analysis, 11 European countries
and, in total, 57 departments.
Test results obtained with the EBS valid in the
study period, during which methylisothiazolinone (MI)
2000 ppmaq. had been added, and the recommended test
concentration of methylchloroisothiazolinone (MCI)/MI
had been increased from 100 to 200 ppm aq., and that
of formaldehyde had been increased from 1% to 2% aq.,
were analysed (25). Altogether, 86 416 patients were
registered who were tested with the EBS and whose
tests were read at least between D3 and D5. The TRUE
Test® employing a hydrocellulose matrix for the haptens
instead of pet. or aq. was used in a relatively small number
of consultations, namely 3649, with the vast majority
of patients being tested with pet.-based and aq.-based
haptens and investigator-loaded chamber systems,
respectively. Moreover, two German departments used a
1-day patch test exposure, applied to 2870 patients. As
in previous analyses, the impact of these variations of the
standard technique was found to be limited, so the results
have all been pooled (26).
Concerning the allergens of the EBS, which form the
basis of the present analysis of polysensitization, the fol-
lowing rules were applied for counting of the number of
individual positive patch test reactions:
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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• Positive reactions to fragrance mix II and hydroxy-
isohexyl 3-cyclohexene carboxaldehyde (HICC)were
pooled, that is, counted as one reaction if one or the
other, or both, were positive.
• The same rule was applied to reactions to mer-
capto mix 1% and 2% pet. (which were never
both tested in one patient) and reactions to
2-mercaptobenzothiazole tested additionally.
• As a marker concerning local anaesthetics, benzo-
caine is tested in the current EBS, whereas caine
mix III is tested by a large number of ESSCA mem-
bers because of its better diagnostic yield; the positive
reaction(s) were counted as one.
• Likewise, sesquiterpene lactone mix is included in
the current EBS, but (partly differing versions of)
Compositae mix were considered to be equivalent,
and positive reaction(s) were counted as one.
• Partly, the mixture of methyldibromo glutaronitrile
(MDBGN) and 2-phenoxyethanol 1:4, for example
Euxyl® K 400, was tested instead of, or in addition
to, MDBGN. All positive reactions were pooled into
one.
• In view of corresponding dithiocarbamates and
thiurams being redox pairs (27), positive reactions
both to zinc diethyldithiocarbamate (ZDEC) or
carba mix – which were never both tested in one
patient – and thiurammix were counted as one.
• Although it could be debated whether positive
reactions to formaldehyde and various formalde-
hyde releasers are truly equivalent, as isolated
reactions to a releaser might be attributable to the
donor molecule, these were also pooled, which con-
cerned quaternium-15, which is presently the only
formaldehyde releaser contained in the EBS.
Besides polysensitization, prevalences are also pro-
vided for oligosensitization, defined as having one or two
positive patch test reactions, but notmore, and for ‘at least
one positive’, also known as the ‘P’ measure (28). For the
polysensitized group and for all patients with no positive
patch test reactions to the EBS, the MOAHLFA (Male,
Occupational dermatitis, Atopic dermatitis, Hand der-
matitis, Face dermatitis, Leg dermatitis, Age ≥40 years)
index is given (29).
To evaluate regional differences for concomitant reac-
tions, that is, pairs of positive reactions contributing
to polysensitization (30), or ‘oligosensitization’, coun-
tries were classified into two regions, as previously done
by Schuttelaar et al. (31). Two regions were defined:
North/Central Europe, comprising Finland, Lithuania,
Poland, Germany, Austria, Switzerland, TheNetherlands,
and the United Kingdom; and South Europe, comprising
Spain, Italy, and Slovenia.
Besides descriptive statistics, adjusted multifactorial
analyses were employed to quantify the independent
association of potentially relevant explanatory factors
and oligosensitization and polysensitization, respectively.
To this end, log-binomial regression analysis was utilized,
which quantifies the association bymeans of a prevalence
ratio (PR), which can be interpreted as a representation
of relative risk. Point estimates were accompanied by
95% confidence intervals (CIs) obtained with the pro-
file likelihood method. The set of explanatory variables
considered included the country, sex, age (dichotomized
as <40 years versus ≥40 years), occupational aetiol-
ogy of contact dermatitis (‘yes’ or ‘partly’ versus ‘no’ or
‘unknown’), atopic dermatitis, past or present, versus
no atopic dermatitis, and the anatomical sites hand,
leg, face, trunk (as reference), and ‘other’. Moreover,
the number of allergens in the baseline series tested was
used as an adjustment factor, as the likelihood of one (or
more) positive reactions depends also on the number of
allergens tested (32).
Results
In the years 2009–2014, altogether 86416 patients
were patch tested in the 57 European departments. The
characteristics of the patients, and univariate results
obtained with the EBS allergens, have been published in a
number of publications covering the 2009–2012 study
period and the 2013–2014 study period, respectively.
For further information, the reader is referred to these
(26, 33–38).
Prevalences of polysensitization across Europe
Crude and age- and sex-standardized prevalences for
polysensitization and oligosensitization, stratified per
country, are presented together with 95%CIs in Table 1.
In order to put these results into perspective, prevalences
for at least one positive reaction (‘P’ measure) and for
negative patch test results are also given (28). No large
differences were seen between crude and standardized
prevalences. Overall, the standardized prevalence of
polysensitization was 7.05%, with the highest standard-
ized prevalences being seen in Austria (12.7%) and The
Netherlands (12.4%), and the lowest in Italy (4.6%)
and Lithuania (5.2%). The standardized ‘P’ measure,
presented as ‘at least one positive reaction’ to the EBS
allergens, was 43.0% for the total population, with con-
siderable variation between countries; from 52.9% in The
Netherlands to 38.6% in the United Kingdom.
Of the total polysensitized population, the proportion
of males aged <40 years was 6.5%, and the proportion
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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of females aged <40 years was 24.3% (Table 2). The
proportion aged ≥40 years and male was 19.9%, and
the majority were female and aged ≥40 years (49.3%).
These proportions were largely similar in the oligosensi-
tized population, except that this populationwas younger.
The MOAHLFA index of the polysensitized population is
shown in Table 3, together with the total patch tested
population as a reference (29). For most of the categories
of the MOAHLFA index, the polysensitized group was
similar to the total patch tested population, except that
the percentage of females was slightly higher for the
polysensitized group, and a higher percentage were aged
≥40 years. This difference in age distribution was most
pronounced in the United Kingdom, whereas, in Spain
and Poland, the percentages were almost the same for
the polysensitized and the total patch tested population.
The distribution of individuals with (a history of) atopic
dermatitis was equal between the totals of both groups;
however, country-specific differences could be seen.
The primary site of dermatitis seemed to be distributed
similarly in both groups overall, as well as for all of the
individual countries.
The most common allergen pairs in polysensitized
individuals and the strengths of patch test reactions
Within the polysensitized group, odds ratios (ORs) were
calculated for all possible allergen pairs to evaluate
concomitant positive patch test reactions. This was per-
formed for the total population, and separately for South
Europe and North/Central Europe as defined above, in
order to observe any differences based on geographical
location. The top 10 allergen pairs per region ranked by
the highest OR are shown in Table 4. Overall, associations
were stronger in South Europe than in North/Central
Europe. For both regions, the top two concomitant reac-
tions were those to quaternium-15/formaldehyde and
carbamix/thiurammix. Themost probable reason for the
concomitant reactions is also suggested in the footnotes
to Table 4.
The most commonly positive EBS allergens in polysen-
sitized patients are shown and compared with those in
oligosensitized patients in Table S1. There were no large
differences regardingwhich allergenswere themost com-
monly positive between the two groups.
The distribution of grades of positive reactions, from
weak positive to extreme positive, in oligosensitized and
polysensitized individuals stratified per country is shown
in Table 5. Overall, for almost all countries, the poly-
sensitized population had a slightly higher percentage of
extreme positive (+++) reactions than the oligosensitized
population. The percentage of strong positive (++) reac-
tions was comparable between both populations, except
for Finland, where the oligosensitized population had
a higher percentage of strong positive reactions than
the polysensitized population. Large differences between
countries can also be observed; for example, the percent-
age of weak positive reactions in the polysensitized popu-
lation in The Netherlands was 81.6%, as compared with
only 21.0% in Spain.
The distribution of grades of positive reactions, per
number of positive reactions, for the total population is
shown as a stacked bar plot in Fig. 1. A clear positive cor-
relation can be seen between the number of positive reac-
tions and the percentage of extreme positive (+++) reac-
tions.
Analysis of risk factors for polysensitization
To assess the influence of country, sex, occupational con-
tact dermatitis (OCD), atopic dermatitis, age ≥40 years
and primary site of dermatitis on the risk of being
polysensitized, a log-binomial regression analysis was
performed (Table 6). The same regression analysis was
performed on the oligosensitized group for comparison.
For quantification of the risk of being either oligo- or
polysensitised associated with the country an individual
has been patch tested in, Switzerland was chosen as
reference, because it is situated between the 2 chosen
European regions. The association between country
and being oligosensitized was minimal; it was lower
in Germany and the United Kingdom (PR=0.79 and
PR=0.82, respectively) than in the reference country,
Switzerland. In contrast, the association between coun-
try and being polysensitized was more pronounced. The
risk of being polysensitized appeared to be significantly
lower for most countries than for Switzerland, and was
especially low in Germany (PR=0.64), Italy (PR=0.59),
and the United Kingdom (PR=0.54). Conversely, this
risk was significantly higher for Austria (PR=1.71) and
The Netherlands (PR=1.27).
Low PRs for male sex in both the oligosensitized and
polysensitized groups (0.7 and 0.59, respectively) indi-
cated that females had a significantly increased risk of
being sensitized overall, and of being polysensitized in
particular. Also, OCD was significantly associated with
both oligosensitization and polysensitization, and again
this association was even stronger for polysensitization.
For atopic dermatitis, a small, significant association was
seen for polysensitization, but not for oligosensitization.
The highest PR for polysensitization was observed for
age ≥40 years (1.71). Of the primary sites of dermatitis,
only hand dermatitis (PR=1.15) was found to be signifi-
cantly associated with polysensitization when compared
withy trunk dermatitis as the reference. Leg dermatitis
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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Table 3. MOAHLFA index per country of patch tested patients in the European Surveillance System on Contact Allergies database between
January 2009 and December 2014 with polysensitization and all patients tested. As Slovenian departments could not contribute information
on occupational dermatitis, atopic dermatitis, and anatomical site, these were omitted from the table.
Country (Sub)group n (total) % M % O % A % H % L % F % A
Austria Polysensitized 219 20.1 19.6 29.2 9.1 2.7 7.3 69.9
All tested 1622 26.4 16.8 21.3 10.1 1.8 5.4 65.5
Switzerland Polysensitized 738 28.9 15.7 24.1 8.7 2.2 5.6 73.7
All tested 7508 38.2 12.9 19.6 9.6 2.2 6.5 66.0
Germany Polysensitized 821 33.0 35.8 27.9 38.0 5.8 9.4 79.3
All tested 11 243 40.8 32.4 26.4 36.2 5.1 9.3 70.2
Spain Polysensitized 430 30.9 19.3 13.0 31.6 7.2 11.9 68.8
All tested 6567 32.0 13.1 14.4 27.5 7.5 13.9 64.8
Finland Polysensitized 112 27.7 34.8 31.2 55.4 4.5 0.9 70.5
All tested 1289 40.5 47.6 30.3 64.2 2.9 4.7 55.7
Italy Polysensitized 594 27.3 8.4 13.5 26.4 4.5 12.3 60.4
All tested 12 893 32.8 5.3 16.8 21.6 6.6 11.6 51.9
Lithuania Polysensitized 85 11.8 14.1 10.6 18.8 22.4 32.9 70.6
All tested 1424 20.2 12.7 11.5 25.5 11.4 24.9 65.3
The Netherlands Polysensitized 904 27.1 22.8 38.5 22.5 4.3 18.3 66.9
All tested 7001 33.1 17.8 34.6 19.7 4.4 18.9 57.4
Poland Polysensitized 586 20.5 26.3 17.2 22.5 3.4 10.9 58.2
All tested 5527 28.6 17.7 16.0 22.3 3.4 11.2 56.1
Slovenia Polysensitized 581 23.2 – – – – – 66.4
All tested 8640 31.1 – – – – – 58.1
United Kingdom Polysensitized 1313 24.3 9.9 31.6 30.2 4.6 26.2 71.7
All tested 22 702 31.3 8.7 36.1 26.0 5.4 27.8 57.0
Total Polysensitized 6383 26.4 21.7 26.1 31.3 5.7 18.0 69.2
All tested 86 416 33.2 16.3 25.7 29.2 6.1 19.2 59.7
M,Male; O, Occupational aetiology; A, Atopic dermatitis (history of); H, Hand dermatitis; L, leg dermatitis; F, face dermatitis; A, age≥40 years.
was inversely significantly associated with oligosensitiza-
tion (PR=0.92).
Discussion
Prevalences of polysensitization
For the first time, prevalences of polysensitization are pre-
sented for different countries across Europe. Overall, the
standardized prevalence of polysensitization was 7.1%,
and the standardized prevalence of oligosensitization was
36.3%. The ‘P’ measure in this dataset was 43.0%, which
is similar to the 43% seen in the ESSCA population patch
tested in 2005–2006 (39). Note that the ‘P’ measure
includes, by definition, both oligosensitized and polysen-
sitized patients, so similarities in association patterns are
to be expected. There is considerable variation in pol-
ysensitization and oligosensitization between countries;
besides reflecting actual sensitization frequencies and the
differences thereof between countries, it can also mainly
be explained by the varying eligibility criteria for patch
testing between departments. Differences between coun-
tries and departments in relation to selection processes
and health systems have been discussed in a previous
ESSCA publication (26). Another explanatory variable is
the length of the baseline series tested in a department;
‘a bigger net catches more fish’. However, in the present
analysis, this effect has a ceiling, in the sense that only
allergens of the EBS as currently recommended were con-
sidered (25), together with possible substitutes or addi-
tions as detailed above, but not any length of departmen-
tal baseline series. Nevertheless, as some national groups
or departments systematically omit haptens from the EBS,
some adjustment for, basically, a lower number of aller-
gens tested in patients (fromone country anddepartment,
respectively) was necessary, and was employed in the
regression analysis. However, the putatively lower sensi-
tivity (and thus lower prevalence yielded) in those depart-
ments still using 100 ppmMCI/MI and 1% formaldehyde,
respectively, has not been separately addressed, as the
effect is regarded as being relatively minor.
The high prevalence of polysensitization in Austria
and The Netherlands may be explained by more restric-
tive patch testing (i.e. more selective) and different pat-
terns of referral, for example in The Netherlands. It seems
unlikely that these countries actuallyhave ahigher preva-
lence of polysensitization, as it does not seem obvious
that individuals in these countries have higher exposure
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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Table 4. Top 10 allergen pairs defined by the highest odds ratios (OR) for the total population and per ‘European region’, accompanied by
a 95%CI, in patch tested patients in the European Surveillance System on Contact Allergies (ESSCA) database between January 2009 to
December 2014 who were polysensitized
Total population South Europe North/Central Europe
Allergen pair OR (95%CI) Allergen pair OR (95%CI) Allergen pair OR (95%CI)
Quaternium-15–
formaldehydea
56.31 (46.55–68.11) Quaternium-15–
formaldehydea
71.62 (48.36–106.07) Quaternium-15–
formaldehydea
49.75 (40.01–61.86)
Carba mix–thiuram mixa 30.84 (26.44–35.97) Carba mix–thiuram mixa 33.77 (22.42–50.86) Carba mix–thiuram mixa 32.44 (27.4–38.4)
Mercaptobenzothiazole/
mercapto mix–thiuram
mixb
13.15 (10.91–15.86) Primin–clioquinolc 24.05 (5.51–104.95) Primin–tixocortol-21-
pivalatec
12.66 (7–22.91)
Tixocortol-21-
pivalate–budesonideb
12.77 (8.91–18.31) Tixocortol-21-
pivalate–clioquinolb
23.43 (3.03–181.34) Mercaptobenzothiazole/
mercapto mix–thiuram mixb
11.81 (9.59–14.55)
Fragrance mix
II/hydroxyisohexyl
3-cyclohexene
carboxaldehyde
–fragrance mix Ib
12.21 (11.33–13.16) Tixocortol-21-
pivalate–budesonideb
23.29 (8.98–60.39) Tixocortol-21-pivalate–
budesonideb
11.38 (7.69–16.84)
Primin–clioquinolc 12.12 (4.35–33.75) Benzocaine/Caine
mix–p-phenylenediaminea
20.60 (15.27–27.79) Potassium dichromate–cobaltb 11.15 (10.11–12.3)
Benzocaine/Caine
mix–p-phenylenediaminea
11.97 (9.92–14.44) Fragrance mix
II/hydroxyisohexyl
3-cyclohexene
carboxaldehyde –fragrance
mix Ib
18.11 (15.26–21.49) Fragrance mix
II/hydroxyisohexyl
3-cyclohexene
carboxaldehyde–
fragrance mix Ib
11.04 (10.16–12)
Potassium
dichromate–cobaltb
11.80 (10.91–12.76) Mercaptobenzothiazole/
mercapto mix–thiuram mixb
17.17 (11.24–26.24) Primin–
mercaptobenzothiazole/
mercapto mixb
10.78 (5.56–20.89)
Tixocortol-21-
pivalate–clioquinolb
10.95 (4.70–25.53) N-isopropyl-N′-phenyl-
4-phenylenediamine–
p-phenylenediaminea
16.53 (11.26–24.26) Clioquinol–paraben mixb 10.40 (3.67–29.46)
N-isopropyl-N′-phenyl-
4-phenylenediamine–
p-phenylenediaminea
10.87 (8.55–13.82) Clioquinol–Myroxylon
pereiraeb
14.94 (6.96–32.05) Neomycin–tixocortol-
21-pivalateb
9.77 (7.14–13.37)
South Europe: Spain, Italy, and Slovenia. North/Central Europe: Finland, Lithuania, Poland, Germany, Austria, Switzerland, The Netherlands, and the United
Kingdom. The most probable reasons for the association are:
across-reaction.
bco-sensitization.
cneither cross-reaction-related or exposure-related.
to baseline allergens than, for example, individuals in
Italy or the United Kingdom. Additional explanations for
variation in polysensitization prevalences seen between
countries are variations in the factors described in the
MOAHLFA index, that is, variations in proportions of
atopic dermatitis, site of dermatitis and OCD in the patch
tested population between countries. Many of these fac-
tors are positively or inversely related to polysensitization,
as discussed below. The effects of age and sex, which cer-
tainly have an influence on polysensitization, on differ-
ences in prevalences between countries have been elim-
inated by using age- and sex-standardized prevalences,
and by adjusting for these factors in the multifactorial
analysis, respectively.
Taking these findings together, it appears that differ-
ences in polysensitization prevalences between countries
are most likely explained by differences in patch tested
populations, possibly patch test methodology, and the
length of the baseline series (within the limit of the actual
EBS set by the present analysis; see above). Therefore,
studies investigating this topic have to take into account
these factors when comparing their results with those of
studies performed in a different department.
Similarly to what has been found in previous stud-
ies, the polysensitized population has a higher propor-
tion of elderly individuals and females than patients with
negative patch test results (1, 40). This is further sup-
ported by the present regression analysis, which shows
that beingmale is a significant risk-lowering factor for pol-
ysensitization, and being aged >39 years is a significant
risk-increasing factor, most likely because of the effect of
cumulative lifetime exposure. Furthermore, the present
analysis was based on allergens of the EBS for better com-
parison, and the EBS may include some allergens of old
relevance (such as clioquinol, primin, and neomycin) and
does not rapidly adopt new allergens. Because of this,
the overall yield of the EBS may be higher in the older
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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Table 5. The distribution of grades of positive reactions (+, ++ versus +++) in oligosensitized and polysensitized patients in the European
Surveillance System onContact Allergies database between January 2009 andDecember 2014, stratified for country. In this analysis, Slovenia
is not included, as the departments only contributed data on reactions being positive or negative; that is, no reaction grades were reported
Oligosensitized Polysensitized
Country N(pat.) N(rea.) % + % ++ % +++ N(pat.) N(rea.) % + % ++ % +++
Austria 629 866 78.6 20.8 0.6 219 863 81.0 16.7 2.3
Switzerland 2849 3779 57.8 31.3 10.9 738 2791 57.0 28.3 14.8
Germany 3722 4889 66.9 26.1 7.0 821 3135 62.5 26.9 10.7
Spain 2523 3367 21.7 60.8 17.5 430 1588 21.0 57.2 21.9
Finland 526 693 26.4 67.5 6.1 112 401 39.9 54.1 6.0
Italy 4855 6184 53.2 37.9 8.9 594 2025 54.8 34.8 10.5
Lithuania 559 739 48.4 36.7 14.9 85 318 51.3 33.3 15.4
The Netherlands 2854 3871 81.4 16.5 2.1 904 3568 81.6 15.9 2.6
Poland 2273 3167 41.3 39.1 19.6 586 2160 40.7 37.8 21.5
United Kingdom 7739 10098 59.8 36.9 3.3 1313 4727 60.1 36.1 3.9
Total 28 529 37 653 56.3 35.5 8.2 5802 21 576 58.6 31.5 9.9
N(pat.), number of patients oligosensitized/polysensitized; N(rea.), total number of reactions of any grade, that is, multiple occurrences are
possible (up to two identical or different reaction grades in oligosensitized patients, up to the observed maximum of 15, and a minimum of
three, in polysensitized patients).
population than in the younger population, and so will
the odds of being polysensitized.
Occupational dermatitis
Occupational dermatitis is a known risk factor for poly-
sensitization; this is most likely attributable to increased
(work-related) exposure to multiple allergens (15, 41).
Another risk factor for occupational dermatitis is wet
work, which increases the risk of acquiring contact
allergy. After age, OCD was most strongly associated with
polysensitization, with a PR of 1.57. Certain countries
contributed a higher proportion of OCD than others,
for example Germany, Finland, and Poland, all three of
which have contributions from departments specialized
in occupational dermatology (33). A higher percentage of
occupational aetiology of dermatitis in the polysensitized
population than in the total patch tested population can
be seen in all countries, except for Finland, where only
34.8% of the polysensitized group had OCD, as com-
pared with 47.6% of all tested individuals. It is unclear
whether this is simply an anomaly, but, without further
investigation, there appears to be no easy explanation.
Atopic dermatitis
In a case–control questionnaire study focusing on poly-
sensitization, 45.1% of polysensitized individuals had a
history of atopic dermatitis, as compared with 31.0%
of oligosensitized individuals (40). Another study, how-
ever, found similar proportions of atopic dermatitis in
polysensitized and oligosensitized populations, which
we also found (42). Atopic dermatitis has been reported
1 2 3 4 5 6 7 8 9
Number of positive reactions
%
0
20
40
60
80
10
0
21 812 9591 3875 1528 577 238 98 35 21
+
++
+++
Fig. 1. The distribution of reaction grades according to the number
of positive reactions to allergens of the departmental baseline series,
each summed up to 100%. The number of patients having one, two
and more positive reactions is indicated on the top x-axis. One
patient each with 15 and 12 positive reactions, 3 patients with 11
positive reactions and 6 patients with 10 positive reactions are
omitted for clarity.
to be a risk factor for polysensitization (15). Whether
atopic dermatitis patients are at higher or lower risk of
developing contact allergy has not been completely elu-
cidated yet; because of immunological differences, atopic
dermatitis patients are less easy to sensitize in an exper-
imental setting; however, this appears to be mitigated by
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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Table 6. Log-binomial regression analysis with oligosensitization and polysensitization as outcomes
Oligosensitization Polysensitization
Factor %(total) PR (95%CI) PR (95%CI)
Switzerland 8.7 1.00 (reference) 1.00 (reference)
Austria 1.9 1.10 (0.98–1.21) 1.71 (1.36–2.13)
Germany 13.0 0.79 (0.75–0.84) 0.64 (0.55–0.74)
Spain 7.6 0.94 (0.89–1.00) 0.74 (0.63–0.87)
Finland 1.5 0.97 (0.89–1.05) 0.84 (0.67–1.03)
Italy 14.9 0.95 (0.90–1.00) 0.59 (0.51–0.69)
Lithuania 1.6 0.99 (0.91–1.07) 0.72 (0.56–0.93)
The Netherlands 8.1 1.04 (0.98–1.10) 1.27 (1.10–1.47)
Poland 6.4 1.00 (0.94–1.07) 1.22 (1.05–1.44)
United Kingdom 26.3 0.82 (0.78–0.87) 0.54 (0.47–0.62)
Male sex 33.2 0.70 (0.68–0.71) 0.59 (0.55–0.63)
Occupational dermatitis 16.3 1.23 (1.20–1.27) 1.57 (1.45–1.69)
Atopic dermatitis 25.7 0.92 (0.90–0.95) 1.09 (1.02–1.16)
Age ≥ 40 years 59.7 1.10 (1.08–1.13) 1.71 (1.60–1.82)
Site: trunk 9.7 1.00 (reference) 1.00 (reference)
Site: hand 29.2 1.03 (0.99–1.08) 1.15 (1.03–1.29)
Site: leg 6.1 0.92 (0.87–0.97) 0.99 (0.86–1.15)
Site: face 19.2 1.03 (0.99–1.07) 1.03 (0.92–1.16)
Site: other 35.8 0.99 (0.95–1.03) 1.04 (0.93–1.16)
PR, prevalence ratio. As Slovenian departments could not contribute information on anatomical site, these were omitted from the analysis.
easier penetration of allergens, owing to an impaired skin
barrier (43), and increased exposure, at least to those
haptens encountered in the treatment of atopic eczema.
Regarding geographical differences, both Italy and Spain
(South Europe) have relatively low percentages of atopic
dermatitis. Also of interest is that, in these countries, a
lower percentage of atopic dermatitis is seen in the poly-
sensitized population than in all individuals tested. The
only other country with this observation is the United
Kingdom; in all other countries, the opposite is found.
Sites of dermatitis
Given the findings of previous studies investigating the
relationship between primary site of dermatitis and poly-
sensitization, it is perhaps surprising that only one of the
sites analysed in the present study was related to poly-
sensitization. One possible explanationmight be that only
five sites were analysed, as opposed to previous studies,
in which between 12 and 19 sites were investigated (15,
44). Some sites previously found to be associated with
polysensitization might have been combined with other
areas in the present analysis, averaging out the previ-
ously found associations. One site of dermatitis that is
widely accepted to be a risk factor for polysensitization
is the lower leg, because of increased exposure to top-
ical medicaments in patients with leg stasis dermatitis
and/or chronic leg ulcers (9). In the present analysis,
however, the site ‘legs’ also included the upper legs, knees,
and popliteal fold. Another reason for the lack of associa-
tion between the legs and polysensitization might be the
decline in frequency of contact allergy in patients suffer-
ing from chronic leg ulcer/stasis dermatitis (45). Alter-
natively, or additionally, it might be that polysensitized
patients suffer from more generalized dermatitis, as sug-
gested byone study, but not confirmedby later studies (44,
46). Dermatitis of the hands is a well-known risk factor
for polysensitization, and this was once again confirmed
in the present analysis (15, 30, 44). More interesting,
perhaps, are the country-specific differences; especially in
Finland and Lithuania, the proportion of patients with
hand dermatitis was lower in the polysensitized group
than in all patch tested patients in those countries. This
might be related to the difference in the proportion of OCD
between the polysensitized and oligosensitized patients in
Finland (discussed above), as handdermatitis oftenhas an
occupational cause (41).
Concomitant reactions in polysensitized individuals
Concomitant patch test reactions can be explained
by various mechanisms; co-sensitization, resulting
from concomitant exposure to unrelated allergens, or
cross-reactivity, resulting from structural similarities
between allergens. Several studies have investigated
associations between allergens, most recently in a publi-
cation by the IVDK (16, 18, 30, 36). Most pairs can be
explained by either co-sensitization through simultane-
ous exposure (for example, at least historically, cobalt and
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potassium dichromate in cement), or by cross-reactivity
[p-phenylenediamine (PPD)–N-isopropyl-N′-phenyl-4-
phenylenediamine and PPD–benzocaine], or both (8,
47). Co-sensitization can result from either exposure to
a product containing different non-related allergens (e.g.
topicals containing fragrances or preservatives), or con-
comitant exposure to different products, for example in
specific occupations. The two most common pairs in our
analysis, in both North/Central and South Europe, were
quaternium-15–formaldehyde and carba mix–thiuram
mix, both with high ORs, providing further justifica-
tion for counting positive reactions to these pairs as
one in the analysis of polysensitization. In a previous
study, 73% of patients with contact allergy to formalde-
hyde also reacted to quaternium-15, and, conversely,
59% of quaternium-15-positive patients also reacted
to formaldehyde (48). Concomitant reactions between
dithiocarbamates and thiurams is a common finding;
the OR of reactions to zinc diethyldithiocarbamate being
coupled with reactions to thiuram mix was 166.43 (i.e.,
extremely high) in a previous study (16).
Ingredients of topical medicaments were often seen
in the top 10 of both regions. One study showed that
a larger proportion of polysensitized patients than of
oligosensitized patients suffer from dermatitis, and that
the dermatitis is of longer duration (for the group with-
out atopic dermatitis) (1). Therefore, this group might
have more intense and longer exposure to several topical
medicaments than oligosensitized patients. An inter-
esting observation is that three pairs contain primin,
twice together with a topical medicament, and once with
mercaptobenzothiazole–mercapto mix. Primin is the
main allergen of Primula obconica H., and primin allergy
occursmainly in florists and gardeners (49). The relation-
ships with clioquinol, an antiseptic agent used in both
topicals and eye drops, and with tixocortol-21-pivalate,
a corticosteroid, are not easily explained. The two might
both be present together in topicals, or used concomi-
tantly/successively to treat dermatitis. Its relationship
withmercaptobenzothiazole–mercaptomix ismost likely
explained by the use of rubber gloves in florists and gar-
deners, or by the presence of mercapto compounds in
fungicides.
There are no large differences between North/Central
and South Europe, and five pairs are present in the top
10 of both regions; quaternium-15–formaldehyde, carba
mix–thiuram mix, tixocortol-21-pivalate–budesonide,
fragrance mix I–fragrance mix II (together with HICC),
and thiuram mix–mercapto mix (together with mer-
captobenzothiazole). Some of the variation between the
two regions might be explained by the fact that some
departments do not test certain allergens in the EBS; for
example, clioquinol is only tested in Spain, Lithuania,
The Netherlands, Poland, and Slovenia.
It is important to note, however, that although the
allergen pairs presented here are often diagnosed together
in 1 patient, this does not reflect actual sensitization
prevalences of the different allergens. For this, the reader
is referred to previous ESSCA publications. For example,
the sensitization prevalence of primin in Europe has con-
siderably decreased in the last decade, most likely as a
result of the introduction of primin-free cultivars of P.
obconica H. in 2000 (33, 50). The same is true for clio-
quinol, with stable low prevalences in the last decade
(<0.5%), so its inclusion in the EBS seems no longer war-
ranted (33, 35, 51).
Strengths of patch test reactions
In the present analysis, a positive correlation was seen
between the number of positive patch test reactions and
the proportion of extreme positive reactions. Similarly,
one study found that individuals with strong or extreme
positive patch test reactionsweremore likely to have addi-
tional positive reactions than individuals with weak posi-
tive reactions (52). Another study found that an extreme
patch test reaction to fragrancemix I was associated with
additional positive reactions (16). A possible explanation
for our findings could be the often mentioned ‘angry
back syndrome’, or ‘excited skin syndrome’, although the
actual existence of these phenomena has been disputed,
and the occurrence is thought to be rare at best (53, 54).
The best explanation for more strong/extreme positive
reactions in polysensitized individuals would be that poly-
sensitization is a sign of heightened susceptibility,which is
also expressedby increased reactivity.Differences between
countries in the distribution of grades of positive reactions
are not easily explained. As the distribution within each
countrywasmore or less comparable for oligosenitization
and polysensitization, a possible explanation could be dif-
ferences in how reactions were read, or differences in the
patch test populations, or differences in the degree of con-
tact sensitization, for example because of varying expo-
sure conditions, as noted before concerning PPD (31).
Limitations
The present analysis is based on only the EBS. As the
chance of observing polysensitization increases with the
number of allergens tested, the oligosensitized subgroup
might include polysensitized individuals, if these had been
tested with a more extended baseline series. Comparison
of prevalences between countries is also made more diffi-
cult byvariations in the lengthof the testedbaseline series,
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as discussed above, particularly in terms of omissions.
For instance, the Austrian, German and Swiss depart-
ments mostly use a baseline series that does not include,
for example, the two corticosteroid markers budesonide
and tixocortol-21-pivalate, as well as benzocaine and
neomycin, but includes other allergens considered to be
important, although these have been disregarded in the
present analysis. In addition, the EBS is prone to contain
old allergens, and is in need for an update. The present
analysis also does not include D7 readings, possibly lead-
ing to an underestimation of single contact allergies (par-
ticularly to corticosteroids) (55), and thereby of polysen-
sitization. Another limitation of this study is that inher-
ent differences between departments and countries, for
example the mode of reading a patch test and different
patterns of referral, make interpretation of the results
difficult.
Conclusion
Differences in polysensitization prevalences are seen
between different countries in Europe, and while many
reasons can be discussed, these differences are not easy
to explain. Along with the variation in contact allergy
prevalences between countries or even departments,
polysensitization varies with the setting, and cannot be
regarded as a fixed characteristic of patch tested patients.
Known risk factors for polysensitization, such high age
and occupational aetiology of dermatitis, were confirmed.
Concomitant reactions to allergen pairs were evaluated
for both South and North/Central Europe, showing no
evidence of strong differences.
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